LCT recruits two patients in Phase II DIABECELL trial

The patient recruitment has been started following the Argentinean approval which permits the company to recruit around eight patients with type 1 diabetes and severe hypoglycaemia.

In the trial, the first two patients have commenced the pre-transplant phase of the trial which will establish a stable baseline from which to compare the post-treatment data to, and determine whether the endpoints have been reached.

Further, the two patients expects to be given first of their two implants in August at the dose of 5,000 Islet Equivalents per kg of body weight (IEQ/kg), followed three months later by their second implant at the same dose.

LCT medical director Bob Elliott said this is an important milestone for LCT and for people with unstable type 1 diabetes.

"This is the third jurisdiction in which DIABECELL will be trialled and the results will contribute to the growing body of evidence to support the need for an alternative treatment to type 1 diabetes," Elliott said.